American Heart Journal
Volume 148, Issue 1 , Pages 72-79 , July 2004

Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: a double-blind, randomized, placebo-controlled study

  • Graham S Hillis, MB, ChB, PhD, MRCP

      Affiliations

    • Department of Cardiology the Royal Infirmary of Edinburgh, Edinburgh, Scotland, UK
    • Corresponding Author InformationReprint requests: Graham Hillis, MB, ChB, PhD, MRCP, Department of Cardiology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, Scotland, UK, AB25 2ZN.
    • ,
  • Claire V Pearson, RGN, BSc Econ, MSc

      Affiliations

    • Department of Cardiology the Royal Infirmary of Edinburgh, Edinburgh, Scotland, UK
    • ,
  • Scott A Harding, MB, ChB, FRACP

      Affiliations

    • Department of Cardiology the Royal Infirmary of Edinburgh, Edinburgh, Scotland, UK
    • ,
  • Sheena Sutherland, MB, ChB, FRCPath

      Affiliations

    • Department of Microbiology University of Edinburgh, Edinburgh, Scotland, UK
    • ,
  • Christopher A Ludlam, MB, ChB, PhD, FRCP, FRCPath

      Affiliations

    • Department of Haematology, the Royal Infirmary of Edinburgh, Edinburgh, Scotland, UK
    • ,
  • John C Marioni, BSc

      Affiliations

    • Department of Public Health Sciences, University of Edinburgh, Edinburgh, Scotland, United Kingdom
    • ,
  • Robin J Prescott, BSc, MSc, PhD, MBCS, CStat

      Affiliations

    • Department of Public Health Sciences, University of Edinburgh, Edinburgh, Scotland, United Kingdom
    • ,
  • Keith A.A Fox, MB, ChB, FRCP

      Affiliations

    • Department of Cardiology the Royal Infirmary of Edinburgh, Edinburgh, Scotland, UK
    • ,
  • Andrew D Flapan, MB, BS, MD, MRCP

      Affiliations

    • Department of Cardiology the Royal Infirmary of Edinburgh, Edinburgh, Scotland, UK

Received 13 February 2003 ,Accepted 21 January 2004.

References 

  1. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–127
  2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143
  3. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365–372
  4. Becker AE, de Boer OJ, van der Wall AC. The role of inflammation and infection in coronary artery disease. Annu Rev Med. 2001;52:289–297
  5. Wong Y-K, Gallagher PJ, Ward ME. Chlamydia pneumoniae and atherosclerosis. Heart. 1999;81:232–238
  6. Grayston JT, Kuo CC, Coulston AS, et al.  Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation. 1995;92:3397–3400
  7. Kuo CC, Grayston JT, Campbell LA, et al.  Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15–34 years old). Proc Natl Acad Sci USA. 1995;92:6911–6914
  8. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease (is there a link?). Lancet. 1997;350:430–436
  9. Gaydos CA, Summersgill JT, Sahney NN, et al.  Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun. 1996;64:1614–1620
  10. Dechend R, Maass M, Gieffers J, et al.  Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappa B and induces tissue factor and PAI-1 expression (a potential link to acclerated arteriosclerosis). Circulation. 1999;100:1369–1373
  11. Summersgill JT, Molestina RE, Miller RD, et al.  Interactions of Chlamydia pneumoniae with human endothelial cells. J Infect Dis. 2000;181(Suppl 3):S479–482
  12. Krull M, Kluchen AC, Wupperman FN, et al.  Signal transduction pathways activated in endothelial cells following infection with Chlamydia pneumoniae. J Immunol. 1999;162:4834–4841
  13. Liuba P, Karnani P, Pesonen E, et al.  Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein E-knockout mice. Circulation. 2000;102:1039–1044
  14. Kalayoglu MV, Perkins BN, Byrne GI. Chlamydia pneumoniae-infected monocytes exhibit increased adherence to human aortic endothelial cells. Microbes Infect. 2001;3:963–969
  15. Fryer RH, Schwobe EP, Woods ML, et al.  Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Invest Med. 1997;454:168–174
  16. Gurfinkel E, Bozovich G, Daroca E, et al.  Randomised trial of roxithromycin in non-Q-wave coronary syndromes (ROXIS pilot study). Lancet. 1997;350:404–407
  17. Gurfinkel E, Bozovich G, Beck E, et al.  Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. Eur Heart J. 1999;20:121–127
  18. Gupta S, Leatham EW, Carrington D, et al.  Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404–407
  19. Anderson JL, Muhlestein JB, Carlquist J, et al.  Randomized secondary prevention trial in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection (the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study). Circulation. 1999;99:1540–1547
  20. Muhlestein JB, Anderson JL, Carlquist JF, et al.  Randomized secondary prevention trial of azithromycin in patients with coronary artery disease (primary clinical results of the ACADEMIC study). Circulation. 2000;102:1755–1760
  21. Stone AFM, Mendall MA, Kaski J-C, et al.  Effect of treatment for Chlamydia pneumoniae and helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes. South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation. 2002;106:1219–1223
  22. Wiesli P, Czerwenka W, Meniconi A, et al.  Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men (a randomized, double-blind placebo-controlled trial). Circulation. 2002;105:2646–2652
  23. O'Connor CM, Dunne MW, Pfeffer MA, et al.  Azithromycin for the secondary prevention of coronary heart disease events. The WIZARD study (a randomized controlled trial). JAMA. 2003;290:1459–1466
  24. Cercek B, Shah PK, Noc M, et al.  Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial (a randomised controlled trial). Lancet. 2003;361:809–813
  25. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics. 1984;40:1079–1087
  26. Saikku P. Epidemiology of Chlamydia pneumoniae in atherosclerosis. Am Heart J. 1999;138:S500–503
  27. Ridker PM, Kundsin RB, Stampfer MJ, et al.  Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation. 1999;99:1161–1164
  28. Gupta S. Chronic infection in the aetiology of atherosclerosis—focus on Chlamydia pneumoniae. Atherosclerosis. 1999;143:1–6
  29. Rodel J, Woytas M, Groh A, et al.  Production of basic fibroblast growth factor and interleukin 6 by human smooth muscle cells following infection with Chlamydia pneumoniae. Infect Immun. 2000;68:3635–3641
  30. Ridker PM, Hennekens CH, Buring JE, et al.  Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ann Intern Med. 1999;131:573–577
  31. de Maat MP, Ossewarde JM, Verheggen PW, et al.  Antibodies to Chlamydia pneumoniae and clinical course in patients with unstable angina pectoris. Atherosclerosis. 2000;153:499–504
  32. Choussat R, Montalescot G, Collet J, et al.  Effect of prior exposure to Chlamydia pneumoniae, Helicobacter pylori, or cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction. Am J Cardiol. 2000;86:379–384
  33. De Backer J, Mak R, De Bacquer D, et al.  Parameters of inflammation and infection in a community based case-control study of coronary heart disease. Atherosclerosis. 2002;160:457–463
  34. Kohara K, Tabara Y, Yamamoto Y, et al.  Chlamydia pneumoniae seropositivity is associated with increased plasma levels of solube cellular adhesion molecules in community-dwelling subjects (the Shimanami Health Promoting Program (J-SHIPP) study). Stroke. 2002;33:1474–1479
  35. Hwang S-J, Ballantyne CM, Sharrett R, et al.  Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases (the Atherosclerosis Risk In Communities (ARIC) study). Circulation. 1997;96:4219–4225
  36. Semann HB, Gurbel PA, Anderson JL, et al.  The effect of chronic azithromycin therapy on soluble endothelium-derived adhesion molecules in patients with coronary artery disease. J Cardiovasc Pharmacol. 2000;36:533–537
  37. Ridker PM, Hennekens CH, Roitmen-Johnson B, et al.  Plasma concentrations of soluble intercellular adhesion molecule-1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88–92
  38. Parchure N, Zouridakis EG, Kaski JC. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation. 2002;105:1298–1303
  39. Richardson M, De Reske M, Delaney K, et al.  Respiratory infection in lipid-fed rabbits enhances sudanophilia and the expression of VCAM-1. Am J Pathol. 1997;151:1009–1017
  40. Saikku P, Leinonen M, Matilla K. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;ii:983–986
  41. Danesh J, Whincup P, Walker M, et al.  Chlamydia pneumoniae IgG titres and coronary heart disease (prospective study and meta-analysis). BMJ. 2000;321:208–213
  42. Miettinen H, Lehto S, Saikku P, et al.  Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland. Eur Heart J. 1996;17:682–688
  43. Saikku P, Leinonen M, Tenkanen L, et al.  Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992;116:273–278
  44. Halme S, Syrjala H, Bliogu A, et al.  Lymphocyte responses to chlamydia antigens in patients with coronary heart disease. Eur Heart J. 1997;18:1095–1101
  45. Leinonen M. Pathogenetic mechanisms and epidemiology of Chlamydia pneumoniae. Eur Heart J. 1993;14(Suppl K):57–61
  46. Grayston JT. Antibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events. Circulation. 1998;97:1669–1670
  47. Neumann F, Kastrati A, Miethke T, et al.  Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3) (a randomised, double blind, placebo-controlled trial). Lancet. 2001;357:2085–2089
  48. Ianaro A, Ialenti A, Maffia P, et al.  Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther. 2000;292:156–163

☆ Supported by the British Heart Foundation.

PII: S0002-8703(04)00055-9

doi: 10.1016/j.ahj.2004.01.016

American Heart Journal
Volume 148, Issue 1 , Pages 72-79 , July 2004

Article Tools